Illinois HB4834 proposes removing testosterone and specified reproductive-health drugs from Prescription Monitoring Program (PMP) reporting and requires purge of existing testosterone PMP records by Jan 1, 2027

HB4834 proposes amendments to the Illinois Controlled Substances Act’s Prescription Monitoring Program provisions (720 ILCS 570/316) to exclude testosterone and certain specified drugs (including mifepristone, misoprostol, GnRH analogues, and estrogen) from PMP applicability as described in the research text. It would also add a new Section 316.2 requiring the Department to purge existing PMP records concerning testosterone by 2027-01-01 and ensure no further testosterone records are created/maintained, with associated rules updates by 2027-01-01. If enacted, this would change PMP reporting scope, downstream analytics, and record retention/purge obligations for covered entities and the administering Department; compliance teams should monitor bill status and assess impacts to PMP submission and data governance processes.